MedTrace Logo

Tracking Triple-negative Breast Cancer Evolution Through Therapy

NCT03077776 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 149

Last updated 2025-02-20

No results posted yet for this study

Summary

A prospective multicentre study which aims to examine the relationship between intratumour heterogeneity (ITH) and pathological response to neoadjuvant chemotherapy in patients with histological confirmation of triple-negative breast cancer (TNBC) who are eligible for neoadjuvant chemotherapy.

Conditions

  • Triple-Negative Breast Neoplasm

Interventions

PROCEDURE

Biopsy

Biopsy of primary tumour to be performed prior to initiation of neoadjuvant chemotherapy

PROCEDURE

Biopsy (optional)

\[Optional\] biopsy of primary tumour to be performed after 4 weeks of neoadjuvant chemotherapy

PROCEDURE

Biopsy (metastatic)

Biopsy of metastatic site to be performed at the time of relapse

Sponsors & Collaborators

  • National Cancer Institute, France

    collaborator OTHER_GOV

  • UNICANCER

    lead OTHER

Principal Investigators

  • Monica ARNEDOS, MD · Gustave Roussy Cancer Campus

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-14
Primary Completion
2024-06-01
Completion
2026-05-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03077776 on ClinicalTrials.gov